Robert Alonso
Director/Board Member at MEDESIS PHARMA S.A.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jean-Claude Maurel | M | - | 21 years | |
Linda P. Dwoskin | F | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 22 years |
John G. Geisler | M | - |
Mitochon Pharmaceuticals, Inc.
Mitochon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mitochon Pharmaceuticals, Inc. operates as a biotech company. It focuses on developing drugs that target the mitochondria for a host of serious diseases. The firm provides products to resolve the over-nutritional phenotype metabolic disorders. The company was founded by Robert Alonso and John G. Geisler in 2014 and is headquartered in Blue Bell, PA. | 10 years |
Olivier Connes | M | - | 6 years | |
Bernard Connes-Lafforet | M | - | 5 years | |
Walt Linscott | M | 63 | 2 years | |
Mario Alcaraz | M | - | - | |
Jean-Marie Cazaledes | M | - | 9 years | |
Cédric Navas | M | - | 6 years | |
Emmanuel Hebert | M | - | 5 years | |
Jean-Philippe Causse | M | - | 3 years | |
Solene Guilliot | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Stephen Tullman | M | 58 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 years |
Kamil Ali-Jackson | F | 65 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 years |
Peter Crooks | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
H. Wilkins | M | 62 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
France | 10 | 62.50% |
United States | 6 | 37.50% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert Alonso
- Personal Network